|
1
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
An JY, Ha TK, Noh JH, Sohn TS and Kim S:
Proposal to subclassify stage IV gastric cancer into IVA, IVB, and
IVM. Arch Surg. 144:38–45. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Songun I, Putter H, Kranenbarg EM, Sasako
M and van de Velde CJ: Surgical treatment of gastric cancer:
15-year follow-up results of the randomised nationwide Dutch D1D2
trial. Lancet Oncol. 11:439–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Izuishi K and Mori H: Recent strategies
for treating stage IV gastric cancer: Roles of palliative
gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver
Dis. 25:87–94. 2016.PubMed/NCBI
|
|
5
|
Tan P and Yeoh KG: Genetics and molecular
pathogenesis of gastric adenocarcinoma. Gastroenterology.
149:1153–1162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan B, Yau EX, Omar Bte SS, Ong CW, Pang
B, Yeoh KG and Salto-Tellez M: A study of HER2 gene amplification
and protein expression in gastric cancer. J Clin Pathol.
63:839–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanner M, Hollmén M, Junttila TT, Kapanen
AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al:
Amplification of HER-2 in gastric carcinoma: Association with
Topoisomerase IIalpha gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hechtman JF and Polydorides AD: HER2/neu
gene amplification and protein overexpression in gastric and
gastroesophageal junction adenocarcinoma: A review of
histopathology, diagnostic testing, and clinical implications. Arch
Pathol Lab Med. 136:691–697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kunz PL, Mojtahed A, Fisher GA, Ford JM,
Chang DT, Balise RR, Bangs CD, Cherry AM and Pai RK: HER2
expression in gastric and gastroesophageal junction adenocarcinoma
in a US population: Clinicopathologic analysis with proposed
approach to HER2 assessment. Appl Immunohistochem Mol Morphol.
20:13–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gómez-Martin C, Garralda E, Echarri MJ,
Ballesteros A, Arcediano A, Rodriguez-Peralto JL, Hidalgo M and
López-Ríos F: HER2/neu testing for anti-HER2-based therapies in
patients with unresectable and/or metastatic gastric cancer. J Clin
Pathol. 65:751–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chua TC and Merrett ND: Clinicopathologic
factors associated with HER2-positive gastric cancer and its impact
on survival outcomes-a systematic review. Int J Cancer.
130:2845–2856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janjigian YY, Werner D, Pauligk C,
Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E,
Tafe LJ, Tang LH, et al: Prognosis of metastatic gastric and
gastroesophageal junction cancer by HER2 status: A European and USA
International collaborative analysis. Ann Oncol. 23:2656–2662.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto K, Fujitani K, Tsujinaka T, Hirao
M, Nishikawa K, Fukuda Y, Haraguchi N, Miyake M, Asaoka T, Miyamoto
A, et al: A case of HER2-positive advanced gastric cancer with
extensive lymph node metastasis treated via chemotherapy with a
trastuzumab-containing regimen followed by conversion surgery. Gan
To Kagaku Ryoho. 41:2296–2298. 2014.(In Japanese). PubMed/NCBI
|
|
15
|
Choda Y, Ninomiya M, Kanazawa T, Sato D,
Tokumoto N, Harano M, Matsukawa H, Ojima Y, Idani H, Shiozaki S, et
al: Gastric cancer with liver metastasis and peritoneal
dissemination treated with conversion surgery to achieve r0
resection after capecitabine, cisplatin, and trastuzumab
chemotherapy-a case report. Gan To Kagaku Ryoho. 41:1421–1424.
2014.(In Japanese). PubMed/NCBI
|
|
16
|
Rüschoff J, Hanna W, Bilous M, Hofmann M,
Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2
testing in gastric cancer: A practical approach. Mod Pathol.
25:637–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen AP, Setser A, Anadkat MJ, Cotliar J,
Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse
events of cancer treatments: The Common Terminology Criteria for
Adverse Events Version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Romero Espejo H and Siancas Navarrete J:
Classification of stomach adenocarcinomas. Rev Gastroenterol Peru.
23:199–212. 2003.(In Spanish). PubMed/NCBI
|
|
20
|
Rahman R, Asombang AW and Ibdah JA:
Characteristics of gastric cancer in Asia. World J Gastroenterol.
20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Japanese Gastric Cancer Association:
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waddell T, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; (European Society for Medical Oncology
(ESMO), : European Society of Surgical Oncology (ESSO); European
Society of Radiotherapy and Oncology (ESTRO): Gastric cancer:
ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 24 Suppl 6:vi57–vi63. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujitani K, Yang HK, Mizusawa J, Kim YW,
Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, et
al: Gastrectomy plus chemotherapy versus chemotherapy alone for
advanced gastric cancer with a single non-curable factor (REGATTA):
A phase 3, randomised controlled trial. Lancet Oncol. 17:309–318.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sougioultzis S, Syrios J, Xynos ID,
Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos
G, Felekouras E, et al: Palliative gastrectomy and other factors
affecting overall survival in stage IV gastric adenocarcinoma
patients receiving chemotherapy: A retrospective analysis. Eur J
Surg Oncol. 37:312–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ,
Park DJ, Kim JH, Kim HH and Lee JS: Survival benefit of gastrectomy
± metastasectomy in patients with metastatic gastric cancer
receiving chemotherapy. Gastric Cancer. 14:130–138. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Terashima M: Conversion therapy for
gastric cancer: Who can make conversion as successful as Goromaru?
Gastric Cancer. 19:685–686. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wada Y, Yoshida K, Hihara J, Konishi K,
Tanabe K, Ukon K, Taomoto J, Suzuki T and Mizuiri H: Sivelestat, a
specific neutrophil elastase inhibitor, suppresses the growth of
gastric carcinoma cells by preventing the release of transforming
growth factor-alpha. Cancer Sci. 97:1037–1043. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wada Y, Yoshida K, Tsutani Y, Shigematsu
H, Oeda M, Sanada Y, Suzuki T, Mizuiri H, Hamai Y, Tanabe K, et al:
Neutrophil elastase induces cell proliferation and migration by the
release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol
Rep. 17:161–167. 2007.PubMed/NCBI
|
|
29
|
Nakajima T, Ota K, Ishihara S, Oyama S,
Nishi M, Ohashi Y and Yanagisawa A: Combined intensive chemotherapy
and radical surgery for incurable gastric cancer. Ann Surg Oncol.
4:203–208. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kanda T, Yajima K, Kosugi S, Ishikawa T,
Ajioka Y and Hatakeyama K: Gastrectomy as a secondary surgery for
stage IV gastric cancer patients who underwent S-1-based
chemotherapy: A multi-institute retrospective study. Gastric
Cancer. 15:235–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshida K, Yamaguchi K, Okumura N,
Tanahashi T and Kodera Y: Is conversion therapy possible in stage
IV gastric cancer: The proposal of new biological categories of
classification. Gastric Cancer. 19:329–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukuchi M, Ishiguro T, Ogata K, Suzuki O,
Kumagai Y, Ishibashi K, Ishida H, Kuwano H and Mochiki E:
Prognostic role of conversion surgery for unresectable gastric
cancer. Ann Surg Oncol. 22:3618–3624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ajani JA, Bentrem DJ, Besh S, D'Amico TA,
Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, et
al: Gastric cancer, version 2.2013: Featured updates to the NCCN
Guidelines. J Natl Compr Canc Netw. 11:531–546. 2013. View Article : Google Scholar : PubMed/NCBI
|
